CLINICAL_TRIALS
trial_result
· 2020-06-17
Clinical Trial Update: A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer [Phase 2]
Summary
Phase 2 trial of prexasertib (LY2606368) in platinum-resistant or refractory recurrent ovarian cancer completed; results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-06-17